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Abstract 1 
Background. Transesophageal echocardiography (TEE) is routinely performed before atrial 2 
fibrillation (AF) transcatheter ablation to exclude the presence of left atrial (LA) or LA appendage 3 
(LAA) thrombi. Aim of the study is to evaluate if easily accessible clinical parameters may relate to 4 
the presence of LA or LAA thrombi to identify patients who could potentially avoid TEE. 5 
Methods and Results. Between January 2012 and September 2014, data from 1,539 consecutive 6 
patients undergoing TEE, as a work-up before AF transcatheter ablation, in six large volume centers 7 
were collected. Baseline clinical features, CHA2DS2-VASc score, transthoracic echocardiography 8 
and presence of thrombi at TEE were recorded. Exclusion criteria were valvular, hypertrophic or 9 
dilated cardiomiopathy, previous heart surgery or an ejection fraction ≤ 35%. Mean age was 59.6 ± 10 
10.4 years, 1,215 (78.9%) were males; 951 (62.9%) presented in sinus rhythm (SR) on admission, 11 
324 (21.1%) had undergone at least one previous ablation and 900 (58.5%) had CHA2DS2-VASc 12 
score 0-1. Thrombi were encountered in 12 patients (0.8%). SR at TEE independently related to the 13 
absence of thrombi (OR 5.15, 95% CI 1.38-19.02, p 0.015); in addition to this, no patient with a 14 
CHA2DS2-VASc score 0-1 and SR on admission presented thrombi at TEE (specificity 100%, 15 
p=0.011).  16 
Conclusion. In a selected population of patients referred for AF ablation, LA/LAA thrombi 17 
prevalence is low. No patients in SR with CHA2DS2-VASc score 0-1 presented LAA thrombi at TEE, 18 
identifying a significant subset of patients who could potentially safely be spared from pre-procedural 19 
TEE.   20 
 21 
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Introduction 1 
Atrial fibrillation (AF) is the most common supraventricular arrhythmia. Its prevalence increases 2 
with age and the number of patients is expected to increase in the next years1. Percutaneous 3 
transcatheter ablation has proven to be safe and effective and the number of procedures performed 4 
worldwide is progressively increasing2. A pre-procedure evaluation, using a transesophageal 5 
echocardiogram (TEE), is commonly used to rule out the presence of thrombi in the left atrium (LA) 6 
or left atrial appendage (LAA)2,3. This examination is generally safe, technically simple and offers 7 
the unique advantage to accurately rule out the presence of LA/LAA thrombi before a procedure 8 
which can be associated with a significant risk of symptomatic3 and asymptomatic thromboembolic 9 
events4. On the other side, this procedure can be time and resource consuming, often scarcely 10 
tolerated by patients and presents a not negligible rate of complications, which can rarely be life-11 
threatening5. A very low prevalence of LA/LAA thrombi, moreover, is reported in patients 12 
undergoing AF ablation6, making a discussion about the risk/benefit ratio of this exam in this setting 13 
mandatory.  14 
For these reasons, it would be of utmost importance to evaluate if any clinical feature may predict the 15 
absence of LA/LAA thrombi and identify those patients who could potentially be spared from a TEE 16 
before AF ablation. The present multicenter study assesses the prevalence of LA/LAA thrombi at 17 
TEE in patients referred for AF ablation procedure in search of easily available clinical parameters 18 
that may relate to LA/LAA thrombosis.   19 
 20 
 21 
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Methods 1 
Medical records of all consecutive patients planned to undergo AF ablation from January 2012 to 2 
September 2014 in six Italian high volume centers were retrospectively reviewed. Inclusion criteria 3 
were all consecutive patients undergoing pre-procedural TEE before (≤ 48 hours) elective AF 4 
transcatheter ablation. In fact, at the time of collection of these data, all centres involved in the study 5 
routinely performed TEE to all patients undergoing AF ablation. Exclusion criteria were the presence 6 
of hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy 7 
(RCM), constrictive pericarditis and valvular cardiomyopathy, defined as valvular defect of at least 8 
moderate grade, previous heart surgery and a left ventricle ejection fraction  (EF) ≤ 35%.  9 
General and clinical data were recorded. Hypertension, dyslipidemia, disthyroidism, diabetes mellitus 10 
were defined and classified according to the current international guidelines; CHA2DS2-VASc score 11 
was computed for each patient.  12 
AF was classified according to current European Society of Cardiology guidelines as paroxysmal, 13 
persistent and long-standing persistent7. Arrhythmia duration was intended as time from the onset of 14 
the first recorded arrhythmic episode.  15 
Patients were treated according to the available latest AF ESC guidelines, particularly regarding 16 
long-term oral anti-thrombotic prophylaxis7. Oral anticoagulation (OAC) prior to AF ablation could 17 
be withdrawn or prosecuted according to physicians and treating centers’ preference; in any case, for 18 
patients withdrawing OAC and/or not on long-term OAC a minimum of a 5 day-course of low-19 
molecular weight heparin at weight adjusted dose (80-100U/Kg every 12 hours) was prescribed.  20 
All patients underwent pre-procedural trans-thoracic echocardiography, and LA/ LAA thrombi or 21 
spontaneous echo contrast  (SEC) were searched for by conventional TEE5. Thrombi were defined as 22 
circumscribed and uniformly echodense intracavitary masses distinct from the underlying LA or 23 
LAA endocardium8. Patients in whom a thrombus was described were temporarily withdrawn from 24 
the AF ablation procedure. Ejection Fraction, antero-posterior LA diameter and LAA dimensions 25 
  5
were classified according to the current guidelines on Chamber Quantification 9. 1 
The study was performed in accordance to the latest Declaration of Helsinki and patients at each 2 
center provided written informed consent to undergo TEE. 3 
 4 
Statistical Analysis 5 
Categorical variables are reported as counts and percentages, while continuous variables as means 6 
and standard deviations. Correlations between parameters and study groups were tested in cross 7 
tabulation tables by means of the Pearson Chi-Square or Fisher’s Exact Test and by one-way 8 
ANOVA respectively for categorical and continuous variables. Sensitivity and specificity predictive 9 
values were assessed for clinical features reporting significant relation with LAA thrombi. 10 
Multivariate analysis was performed by a logistic binary regression model including parameters 11 
known to predict LAA thrombi and/or with a statistically significant relationship (p <0.05) with the 12 
presence of LAA thrombi at univariate analysis.   13 
A two sided p-value <0.05 was considered statistically significant; all analyses were performed with 14 
SPSS 21.0 (IBM Corporation, Armonk, NY, USA). 15 
 16 
 17 
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Results  1 
A total of 1,539 patients were enrolled, of whom 1,215 (78.9%) males; 864 (56.2%) presented 2 
paroxysmal AF, 753 (48.9%) had hypertension and 66 (4.5%) suffered previous stroke or transient 3 
ischemic attack (TIA); on admission, 951 (62.9%) were in sinus rhythm (SR, Table 1). Nine hundred 4 
patients (58.5%) presented a CHA2DS2-VASc score of 0-1. Overall, 589 (56.2%) were on active 5 
OAC treatment with a vitamin-K antagonists (VKA), 6 (0.4%) with novel oral anticoagulants 6 
(NOAC). Overall, 164 (10.7%) patients were excluded due to the following exclusion criteria: 11 for 7 
HCM, 39 for DCM, one for constrictive pericarditis, 79 for valvular heart disease, 18 for previous 8 
heart surgery, 16 for EF ≤ 35%.  9 
At TEE performed before the AF ablation procedure, LAA thrombi were detected in 12 patients 10 
(0.8%). All patients with LAA thrombi were on OAC with VKA, excepted two with CHA2DS2-11 
VASc score 1.  Among the patients with thrombi at TEE (Table 2), all of those with a CHA2DS2-12 
VASc score 0-1 were in AF at the moment of the TEE, while the remaining 3 patients that were in 13 
SR during TEE presented a CHA2DS2-VASc score of 2 or higher. Seven of these patients were 14 
undergoing a first ablation procedure; only one was in SR at the moment of TEE (CHA2DS2-VASc 15 
score 3). At univariate analysis (Table 1), presence of AF during TEE and undergoing a redo 16 
procedure, related to the presence of thrombi at TEE (p=0.024, p=0.001, respectively). No patient 17 
with CHA2DS2-VASc score ≤ 1 and SR on admission presented thrombi at TEE (p=0.011, Figure 1). 18 
Only one patient on SR undergoing a first procedure presented a thrombus at TEE (CHA2DS2-VASc 19 
score 3). At multivariate analysis, adjusting for SR during TEE, CHA2DS2-VASc score 0-1, 20 
undergoing a first procedure, only SR at TEE significantly related to the absence of thrombi (OR 21 
5.15, 95% CI 1.38-19.02, p 0.015).  22 
As expected, prevalence of SEC was significantly higher in patients with LAA thrombi (91 23 
(6.1%) vs. 5 (50%), p < 0.001). 24 
Specificity and predictive values for the absence of thrombi at TEE were assessed for the 25 
  7
clinical variables emerged at univariate analysis or known to relate to LA/LAA thrombi. Individually 1 
CHA2DS2-VASc score as well as undergoing AF ablation for the first time reported a low specificity 2 
(58.5% and 41.7, respectively), while a higher specificity (75.0%) was reported for heart rhythm on 3 
admission and, even more, for presenting with SR at TEE while referred for the first procedure 4 
(90.0%). No patients with CHA2DS2-VASc score 0-1 and SR at TEE presented LAA thrombi at TEE, 5 
with a positive predictive value of 100% for the absence of thrombi for the combination of these two 6 
parameters.  7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
  8
Discussion 1 
The main findings of our study are 1) that prevalence of LA/LAA thrombi in selected, 2 
consecutive patients referred for AF ablation is extremely low; 2) presence of SR on admission and a 3 
low-intermediate CHA2DS2-VASc score, especially in patients undergoing first AF ablation, relate to 4 
the absence of LA/LAA thrombi at TEE.  5 
AF ablation is an interventional procedure that is becoming a mainstay in the management of 6 
AF 7,10. Despite its widespread diffusion, questions concerning pre-procedural management, as the 7 
systematic need for TEE to exclude LA/LAA thrombi, still remain open. Not even the 2012 8 
HRS/EHRA/ECAS consensus document on AF ablation reached an unanimous agreement on pre-9 
procedural TEE indications, only suggesting TEE should be reserved to patients with AF on 10 
admission, especially when persisting from more than 48 hours11. In fact, to date, given the difficulty 11 
of certifying OAC effect over the weeks preceding the procedure and the hazard of presenting a 12 
thrombi despite therapeutic OAC, the majority, but not all, of the centers routinely perform TEE 13 
before the AF ablation despite correct anticoagulation 2,3,12. In fact, in Europe, about 2 out of 3 14 
patients undergo TEE prior to AF ablation, without major significant regional differences13.  15 
Our study included a selected population of patients without major structural 16 
cardiomyopathies undergoing AF ablation and is, to the best of our knowledge, the largest available 17 
series assessing this issue. Despite the strict selection criteria, the population included in our study is 18 
well representative of a relevant share of subjects undergoing AF ablation in European centers in the 19 
time span considered for our analysis13. A very low prevalence of LA/LAA thrombi is reported, 20 
however the prospective study by Puwanant et al. reported a similar prevalence of LAA thrombi 21 
(0.6%)6; in the European Atrial Fibrillation Ablation Pilot Study 7 patients out of 1410 did not 22 
undergo AF ablation due to a LAA thrombus. A slightly higher prevalence was reported instead in 23 
other experiences (ranging between 1.6%-3.6%), that, however, included patients at higher risk of 24 
thrombotic events who were excluded in our multicenter study (e.g. history of congestive heart 25 
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failure, structural heart disease, cardiomyopathies and valvular heart disease) 14, 15,16,17, 18,19.  1 
In the population included in the present study, SR at TEE, and referral for first AF ablation 2 
procedure significantly related to the absence of thrombi at TEE. Of note, also the presence of SEC at 3 
TEE related to the presence of LA/LAA thrombi (5.9 vs. 50.0%, respectively in patients without and 4 
with LA/LAA thrombi; p<0.001). Given the aim of the study to identify easily available features 5 
relating to the presence of LA/LAA thrombi, this parameter has intentionally not been considered 6 
within predictors; in any case, its presence, provided that no thrombi were detectable, did not prevent 7 
patients from undergoing the procedure. 8 
SR at TEE was the only independent predictor of LA/LAA thrombi at multivariate analysis. 9 
In addition, no patients in SR and with a CHA2DS2-VASc score of 0-1 presented thrombi at TEE. 10 
These results are consistent with those reported in previous studies: in seven prior series, only 5 11 
patients with a CHADS2 or CHA2DS2-VASc score of 0 presented thrombi at TEE6,14,15,16,17,18,19. Of 12 
these five patients only two were on SR at the time of TEE14,17,18,19. The present findings therefore 13 
confirm that a clinical assessment combining two simple parameters, heart rhythm and CHA2DS2-14 
VASc score, may help to identify a relevant amount of patients (35.1% in our series) with a very low 15 
probability of presenting LA/LAA thrombi at TEE prior to AF ablation. A history of a previous AF 16 
ablation, instead, related to the presence of LA/LAA thrombi also in a previous study of Wallace et 17 
al18. This result may depend on the fact that a previous transcatheter ablation may determine 18 
increased atrial fibrosis20, while AF relapses following failure of a first procedure may relate to 19 
decreased atrial function and increased LA dimensions21, all predisposing substrates for thrombus 20 
formation and consequent thromboembolic risk.  21 
In the present study, less than 60% of the patients not presenting a thrombus and slightly more 22 
than 30% of the patients in SR with low-intermediate CHA2DS2-VASc score were on long-term 23 
OAC before ablation. On the whole, all patients received at least a course of 5 days of low-molecular 24 
weight heparin before the TEE, remarking how the risk of LA/LAA thrombi is, in reality, in a general 25 
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population referred for AF ablation, quite low. These results may lead, in any case, to reconsider the 1 
appropriateness of executing TEE in all patients undergoing AF ablation.  2 
In general, the present is a highly selected population with a low probability of LAA thrombi. 3 
Generalization of the present findings is therefore bound to subjects with similar characteristics. In 4 
fact, enrolment in the study was obtained after thorough TTE assessment in search of the declared 5 
exclusion criteria. Previous literature has proposed several TTE parameters, not considered in the 6 
present study, potentially related to an increased prevalence of LAA thrombi (i.e diastolic 7 
dysfunction, pulmonary hypertension, severe right atrial enlargement, poor LA function at speckle 8 
tracking22). These TTE features, especially when the hereby-proposed features suggest sparring a 9 
TEE, therefore candidate as reliable parameters to minimize potential residual risks.  Indeed TEE is a 10 
safe and low expensive exam, which offers undeniable results in the search of LA/LAA thrombi, but 11 
the risk-benefit ratio of its use in the AF ablation setting should be carefully re-assessed. TEE 12 
presents a low, but still not negligible, risk of complications (0.8-2.8%)5, and, in addition, may 13 
determine an unjustified increase in the health-care related costs other than being often poorly 14 
tolerated by the patients23. In conclusion, in our opinion, a careful risk/benefit ratio evaluation and 15 
prospective studies are needed to corroborate the comparative safety of an extensive vs. selective use 16 
of TEE prior to AF ablation. 17 
 18 
Study limitations 19 
The following limitations must be taken into account. First, this report is retrospective: 20 
study cohort may therefore be biased by patient selection by physician in charge. Second, 21 
multivariate analysis is based on a low number of events and is consequently limited in 22 
statistical power. The results of our study have consequently to be considered primarily 23 
as hypothesis generating. Third, as the aim of our study was to identify easily available 24 
features relating to the presence of LA/LAA thrombi, advanced and TEE parameters were 25 
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intentionally not included in the analysis.  More specifically, thorough diastolic (i.e. DTI 1 
E/e’) or LA function (i.e. by strain and/or speckle tracking) assessment, number of LAA 2 
lobes and peak flow velocity were not available, as they were not part of clinical routine 3 
when excluding thrombi at pre-procedural TEE; eventually LAA morphology was not 4 
assessed due to need for 3D segmentation techniques not routinely performed in all the 5 
centers involved24 25. Eventually, data concerning anticoagulation relate to prescribed and 6 
not effective treatment; for this reason, any conclusion on this topic has been avoided. 7 
Moreover, very few patients on NOAC were included, limiting generalization to patients 8 
on NOAC.  9 
 10 
 11 
Conclusions 12 
The present study shows that careful patient selection and a simple clinical assessment including 13 
CHA2DS2-VASc score, heart rhythm on admission, and ablation history may identify a relevant 14 
subset of patients with a very low probability of LA/LAA thrombi, who could be potentially safely 15 
spared from TEE before AF transcatheter ablation. 16 
 17 
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Table 1. Baseline clinical and echocardiographic characteristics of the study population stratified 
according to the presence of left atrial appendage thrombi. Values reported as counts and percentage, 
if not differently stated. P value by Pearson Chi-Square/Fisher’s Exact Test or ANOVA. 
Characteristics Overall population n = 1539 
No LAA thrombus 
n = 1527 
LAA thrombus 
n = 12 p value 
Age (years) 59.6 ± 10.4 59.6 ±11.3 59.1 ± 19.4 0.887 
Male 1215 (78.9) 1206 (79.0) 9 (75%) 0.724 
BMI 19.0 ± 12.7 19.0 ±12.7 23.3 ± 11.5 0.412 
Hypertension 753 (48.9) 745 (48.8) 8 (66.7) 0.256 
Dislipidemia 237 (18.4) 235 (18.4) 2 (16.7) 0.990 
PreviousStroke/TIA 66 (4.5) 65 (4.5) 1 (8.3) 0.800 
Diabetes 89 (6.2) 89 (6.3) 0 (0) 0.371 
Cha2ds2Vasc        
0 
1 
2 
≥ 3 
 
405 (26.3) 
495 (32.2) 
382 (24.8) 
257 (16.7) 
 
403 (26.4) 
492 (32.2) 
379 (24.8) 
253 (16.6) 
 
2 (16.7%) 
3 (25.0%) 
3 (25.0%) 
4 (33.3%) 
0.297 
Paroxysmal AF 
Persistent AF 
Long-standing persistent AF 
864 (56.2) 
620 (40.3) 
48 (3.1) 
860 (56.4) 
615 (40.3) 
48 (3.1) 
4 (33.3) 
5 (45.5) 
0 (0.0) 
 
AF duration (months) 56.3 ± 66.0 56.4 ± 66.1 47.2 ± 48.5 0.756 
First AF ablation procedure 1215 (79.0) 1208 (79.1) 7 (58.4) <0.001 
Sinus rhythm at admission 951 (62.9) 948 (63.2) 3 (25.0%) 0.024 
OAC 589 (56.2) 579 (55.9) 10 (83.3%) 0.078 
TT Echocardiographic parameters     
LVEF (%) 60.5 ± 6.6 60.0 ± 5.6 60.6 ± 6.5 0.819 
LA volume (ml) 84.8 ± 39.3 117.7 ± 25.4 84.7 ± 39.4 0.149 
Left atrium AP diameter (mm) 45.2 ± 6.7 45.2 ± 6.7 51.5 ± 8.9 0.061 
BMI, body mass index; TIA, transient ischemic attack; AF, atrial fibrillation; AP, antero-posterior; LA, left 
atrium; LAA, left atrial appendage; LVEF, left ventricular ejection fraction; OAC, oral anticoagulation; TT, 
transthoracic  
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Table 2. Detailed clinical features of patients presenting with left atrial or left atrial appendage 
thrombus at transesophageal echocardiography. 
Patient Age Sex CHA2DS2-VASc score First procedure 
Long term 
OAC 
Heart rhythm 
at TEE 
Oral 
anticoagulation 
1 67 M 2 NO Yes AF Yes 
2 65 F 5 No Yes SR Yes 
3 77 M 3 No Yes AF Yes 
4 63 M 1 Yes No AF No  
5 59 F 1 No No AF No 
6 65 M 2 No Yes SR Yes 
7 56 M 0 Yes Yes AF Yes 
8 63 M 3 Yes Yes SR Yes 
9 69 F 2 Yes Yes AF Yes 
10 58 M 2 Yes Yes AF Yes 
11 35 M 0 Yes Yes AF Yes 
12 67 M 1 Yes Yes AF Yes 
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Table 3. Sensitivity and specificity predictive values for the clinical features showing a significant 
correlation for the absence of left atrial/left atrial appendage thrombi. 
 
 Specificity Sensitivity PPV NPV 
CHA2DS2-VASc 0-1 58.5 58.3 99.4 1.1 
SR at TEE 75.0 62.1 99.7 1.9 
First Procedure 41.7 79.1 99.4 1.6 
CHA2DS2-VASc score 0-1 and 
SR at TEE 100.0 35.2 100.0 1.2 
SR at TEE and First Procedure 90.0 50.2 99.9 3.9 
SR at TEE and CHA2DS2-VASc 
0-1 and First Procedure 100.0 55.5 100.0 1.7 
 
 
 
 NPV, negative predictive value; PPV, positive predictive value 
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Figure titles and legends: 
Figure 1. Heart Rhythm, CHA2DS2-VASc score and Left Atrial or Left Atrial Appendage 
Thrombi. Prevalence of left atrial or left atrial appendage thrombi stratified according to heart 
rhythm on admission and CHA2DS2-VASc score (SR, sinus rhythm; AF, atrial fibrillation). 
 
 
 
 
